RCMI Coordinating Center (RCMI CC) Header Logo

Connection

James Lillard to Humans

Back to Details
This is a "connection" page, showing publications James Lillard has written about Humans.
James Lillard
Connection Strength
0.582
Humans
  1. Lillard JW, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2022 Nov 01; 128(21):3787-3795.
    View in: PubMed
    Score: 0.043
  2. Ohandjo AQ, Liu Z, Dammer EB, Dill CD, Griffen TL, Carey KM, Hinton DE, Meller R, Lillard JW. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment. Sci Rep. 2019 10 18; 9(1):14963.
    View in: PubMed
    Score: 0.035
  3. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec; 45(6):2232-40.
    View in: PubMed
    Score: 0.025
  4. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr; 141(4):514-30.
    View in: PubMed
    Score: 0.024
  5. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18; 12:64.
    View in: PubMed
    Score: 0.022
  6. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May; 38(5):1279-85.
    View in: PubMed
    Score: 0.019
  7. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
    View in: PubMed
    Score: 0.018
  8. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22; 9:85.
    View in: PubMed
    Score: 0.018
  9. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25; 5(2):e9432.
    View in: PubMed
    Score: 0.018
  10. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15; 125(10):2288-95.
    View in: PubMed
    Score: 0.018
  11. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28; 283(1):29-35.
    View in: PubMed
    Score: 0.017
  12. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun; 86(3):215-23.
    View in: PubMed
    Score: 0.017
  13. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 04; 9:25.
    View in: PubMed
    Score: 0.016
  14. Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets. 2007 Jun; 7(2):111-23.
    View in: PubMed
    Score: 0.015
  15. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug; 75(8):3722-8.
    View in: PubMed
    Score: 0.015
  16. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004 Dec 15; 10(24):8743-50.
    View in: PubMed
    Score: 0.012
  17. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004 Dec; 84(12):1666-76.
    View in: PubMed
    Score: 0.012
  18. Singh UP, Singh S, Ravichandran P, Taub DD, Lillard JW. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J Immunol. 2004 Nov 01; 173(9):5509-16.
    View in: PubMed
    Score: 0.012
  19. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J. 2022 03 17; 12(3):43.
    View in: PubMed
    Score: 0.010
  20. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722.
    View in: PubMed
    Score: 0.010
  21. Singh SK, Gordetsky JB, Bae S, Acosta EP, Lillard JW, Singh R. Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer. Cells. 2020 08 27; 9(9).
    View in: PubMed
    Score: 0.009
  22. Noel B, Singh SK, Lillard JW, Singh R. Role of natural compounds in preventing and treating breast cancer. Front Biosci (Schol Ed). 2020 03 01; 12(1):137-160.
    View in: PubMed
    Score: 0.009
  23. Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett. 2019 07 10; 454:1-13.
    View in: PubMed
    Score: 0.008
  24. Mir H, Kaur G, Kapur N, Bae S, Lillard JW, Singh S. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep. 2019 02 21; 9(1):2527.
    View in: PubMed
    Score: 0.008
  25. Lillard JW, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A. 1999 Jan 19; 96(2):651-6.
    View in: PubMed
    Score: 0.008
  26. LillardJr JW, Bearden SW, Fetherston JD, Perry RD. The haemin storage (Hms+) phenotype of Yersinia pestis is not essential for the pathogenesis of bubonic plague in mammals. Microbiology (Reading). 1999 Jan; 145 ( Pt 1):197-209.
    View in: PubMed
    Score: 0.008
  27. Singh SK, Lillard JW, Singh R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018 07 28; 427:49-62.
    View in: PubMed
    Score: 0.008
  28. Singh SK, Mishra MK, Eltoum IA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018 01 22; 8(1):1323.
    View in: PubMed
    Score: 0.008
  29. Lillard JW, McGhee JR. Adjuvants or live delivery systems for the characterization of mucosal T helper subset responses. Res Immunol. 1997 Oct-Dec; 148(8-9):520-7.
    View in: PubMed
    Score: 0.008
  30. Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017; 12:6205-6218.
    View in: PubMed
    Score: 0.008
  31. Stewart T, Koval WT, Molina SA, Bock SM, Lillard JW, Ross RF, Desai TA, Koval M. Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway. Exp Cell Res. 2017 06 15; 355(2):153-161.
    View in: PubMed
    Score: 0.007
  32. Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017 Mar 07; 8(10):17216-17228.
    View in: PubMed
    Score: 0.007
  33. Banerjee S, Singh SK, Chowdhury I, Lillard JW, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017 03 01; 9(2):235-245.
    View in: PubMed
    Score: 0.007
  34. Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget. 2017 Feb 14; 8(7):11302-11315.
    View in: PubMed
    Score: 0.007
  35. Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Front Biosci (Landmark Ed). 2017 01 01; 22(3):428-450.
    View in: PubMed
    Score: 0.007
  36. Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016 06 14; 114(12):1343-51.
    View in: PubMed
    Score: 0.007
  37. Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and av?3 integrin clustering. Oncotarget. 2016 Feb 09; 7(6):7343-53.
    View in: PubMed
    Score: 0.007
  38. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
    View in: PubMed
    Score: 0.007
  39. Zhang W, Yi B, Wang C, Chen D, Bae S, Wei S, Guo RJ, Lu C, Nguyen LL, Yang WH, Lillard JW, Zhang X, Wang L, Liu R. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells. Clin Cancer Res. 2016 05 15; 22(10):2545-54.
    View in: PubMed
    Score: 0.007
  40. Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30; 6(12):9985-98.
    View in: PubMed
    Score: 0.006
  41. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30; 5(20):10170-9.
    View in: PubMed
    Score: 0.006
  42. Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, Gupta RC. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol. 2011 Oct; 39(4):941-7.
    View in: PubMed
    Score: 0.005
  43. Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 06 01; 3(4):1569-82.
    View in: PubMed
    Score: 0.005
  44. Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
    View in: PubMed
    Score: 0.005
  45. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
    View in: PubMed
    Score: 0.005
  46. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010 Mar 01; 70(4):341-52.
    View in: PubMed
    Score: 0.004
  47. Zuba-Surma EK, Kucia M, Abdel-Latif A, Lillard JW, Ratajczak MZ. The ImageStream System: a key step to a new era in imaging. Folia Histochem Cytobiol. 2007; 45(4):279-90.
    View in: PubMed
    Score: 0.004
  48. Fang Z, Miao Y, Ding X, Deng H, Liu S, Wang F, Zhou R, Watson C, Fu C, Hu Q, Lillard JW, Powell M, Chen Y, Forte JG, Yao X. Proteomic identification and functional characterization of a novel ARF6 GTPase-activating protein, ACAP4. Mol Cell Proteomics. 2006 Aug; 5(8):1437-49.
    View in: PubMed
    Score: 0.003
  49. Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, Lillard JW, Stiles JK. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malar J. 2005 Dec 16; 4:63.
    View in: PubMed
    Score: 0.003
  50. Barr EL, Ouburg S, Igietseme JU, Morr? SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard JW, Black CM, Ananaba GA. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect. 2005 Aug; 38(4):244-54.
    View in: PubMed
    Score: 0.003
  51. Bumpers HL, Huang MB, Powell M, Grizzle WE, Lillard JW, Okoli J, Bond VC. Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer. Cancer Biol Ther. 2005 Jan; 4(1):65-9.
    View in: PubMed
    Score: 0.003
  52. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW, Taub DD. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004 Jul; 114(1):57-66.
    View in: PubMed
    Score: 0.003
  53. Sarfo BY, Singh S, Lillard JW, Quarshie A, Gyasi RK, Armah H, Adjei AA, Jolly P, Stiles JK. The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann Trop Med Parasitol. 2004 Apr; 98(3):297-303.
    View in: PubMed
    Score: 0.003
  54. Boyaka PN, Lillard JW, McGhee J. Interleukin 12 and innate molecules for enhanced mucosal immunity. Immunol Res. 1999; 20(3):207-17.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support